{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:14:31Z","timestamp":1792134871582,"version":"4.4.0"},"reference-count":113,"publisher":"Oxford University Press (OUP)","issue":"Supplement_9","license":[{"start":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:00:00Z","timestamp":1714780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Meningiomas are the most common intracranial neoplasms in adults. While most meningiomas are cured by resection, further treatment by radiotherapy may be needed, particularly in WHO grades 2 and 3 tumors which have an increased risk of recurrence, even after conventional therapies. Still, there is an urgent need for novel therapeutic strategies after the exhaustion of local treatment approaches. Radionuclide therapies combine the specificity of tumor-specific antibodies or ligands with the cytotoxic activity of radioactive emitters. Alongside this, integrated molecular imaging allows for a noninvasive assessment of predictive biomarkers as treatment targets. Whereas the concept of \u201ctheranostics\u201d has initially evolved in extracranial tumors such as thyroid diseases, neuroendocrine tumors, and prostate cancer, data from retrospective case series and early phase trials underscore the potential of this strategy in meningioma. This review aims to explore the available evidence of radionuclide treatments and ongoing clinical trial initiatives in meningioma. Moreover, we discuss optimal clinical trial design and future perspectives in the field, including compound- and host-specific determinants of the efficacy of \u201ctheranostic\u201d treatment approaches.<\/jats:p>","DOI":"10.1093\/neuonc\/noae069","type":"journal-article","created":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T19:27:59Z","timestamp":1711740479000},"page":"S215-S228","source":"Crossref","is-referenced-by-count":27,"title":["Radioligand therapies in meningioma: Evidence and future directions"],"prefix":"10.1093","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6537-3874","authenticated-orcid":false,"given":"Maximilian J","family":"Mair","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, LMU Hospital, LMU Munich , Munich ,","place":["Germany"]},{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Tabouret","sequence":"additional","affiliation":[{"name":"Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, GlioME Team, plateforme PETRA, CHU Timone, Service de Neurooncologie , Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic , Rochester, Minnesota ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik P","family":"Sulman","sequence":"additional","affiliation":[{"name":"Brain and Spine Tumor Center, Laura and Isaac Perlmutter Cancer Center, NYU Langone , New York, New York ,","place":["USA"]},{"name":"Department of Radiation Oncology, New York University Grossman School of Medicine , New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7700","authenticated-orcid":false,"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber Cancer Institute , Boston, Massachusetts ,","place":["USA"]},{"name":"Department of Neurology, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-2315","authenticated-orcid":false,"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine I, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie L","family":"Albert","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, LMU Hospital, LMU Munich , Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,4]]},"reference":[{"key":"2024121023462362100_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20142020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro Oncol"},{"issue":"8","key":"2024121023462362100_CIT0002","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"14","key":"2024121023462362100_CIT0003","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1002\/cam4.2516","article-title":"Trends in intracranial meningioma incidence in the United States, 2004-2015","volume":"8","author":"Lin","year":"2019","journal-title":"Cancer Med"},{"key":"2024121023462362100_CIT0004","doi-asserted-by":"crossref","first-page":"101562","DOI":"10.1016\/j.canep.2019.07.001","article-title":"Incidence, mortality and outcome of meningiomas: A population-based study from Germany","volume":"62","author":"Holleczek","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"6","key":"2024121023462362100_CIT0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00401-023-02642-5","article-title":"Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: Comprehensive molecular analysis of EORTC 22042-26042","volume":"146","author":"Maas","year":"2023","journal-title":"Acta Neuropathol."},{"issue":"5","key":"2024121023462362100_CIT0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: A multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"12","key":"2024121023462362100_CIT0007","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1038\/s41591-023-02586-z","article-title":"Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses","volume":"29","author":"Chen","year":"2023","journal-title":"Nat Med."},{"issue":"11","key":"2024121023462362100_CIT0008","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/neuonc\/noab150","article-title":"EANO guideline on the diagnosis and management of meningiomas","volume":"23","author":"Goldbrunner","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024121023462362100_CIT0009","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11060-022-04148-8","article-title":"Emerging systemic treatment options in meningioma","volume":"161","author":"Mair","year":"2023","journal-title":"J Neurooncol."},{"issue":"12","key":"2024121023462362100_CIT0010","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s12149-022-01806-9","article-title":"Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics","volume":"36","author":"Hertz","year":"2022","journal-title":"Ann Nucl Med."},{"issue":"4","key":"2024121023462362100_CIT0011","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41591-022-01759-6","article-title":"Theranostics could be big business in precision oncology","volume":"28","author":"Arnold","year":"2022","journal-title":"Nat Med."},{"issue":"9","key":"2024121023462362100_CIT0012","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.crad.2017.05.002","article-title":"Meningioma mimics: Five key imaging features to differentiate them from meningiomas","volume":"72","author":"Starr","year":"2017","journal-title":"Clin Radiol."},{"issue":"1","key":"2024121023462362100_CIT0013","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): A report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"2024121023462362100_CIT0014","first-page":"1865","article-title":"Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A","volume":"6","author":"Schulz","year":"2000","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2024121023462362100_CIT0015","first-page":"485","article-title":"Sstr2A immunohistochemical expression in human meningiomas: Is there a correlation with the histological grade, proliferation or microvessel density","volume":"20","author":"Barresi","year":"2008","journal-title":"Oncol Rep."},{"issue":"5","key":"2024121023462362100_CIT0016","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5414\/NPP27334","article-title":"Expression of c-Myc, neurofibromatosis Type 2, somatostatin receptor 2 and erb-B2 in human meningiomas: relation to grades or histotypes","volume":"27","author":"Durand","year":"2008","journal-title":"Clin Neuropathol."},{"issue":"1","key":"2024121023462362100_CIT0017","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/his.12366","article-title":"Comparative study of soft tissue perineurioma and meningioma using a five-marker immunohistochemical panel","volume":"65","author":"Agaimy","year":"2014","journal-title":"Histopathology."},{"issue":"8","key":"2024121023462362100_CIT0018","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00701-018-3575-z","article-title":"SSTR-2 as a potential tumour-specific marker for fluorescence-guided meningioma surgery","volume":"160","author":"Dijkstra","year":"2018","journal-title":"Acta Neurochir (Wien)."},{"issue":"1","key":"2024121023462362100_CIT0019","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10143-021-01552-y","article-title":"Differences in the expression of SSTR1-5 in meningiomas and its therapeutic potential","volume":"45","author":"Behling","year":"2022","journal-title":"Neurosurg Rev."},{"issue":"5","key":"2024121023462362100_CIT0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/neuonc\/nor044","article-title":"Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma","volume":"13","author":"Johnson","year":"2011","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024121023462362100_CIT0021","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1212\/WNL.0000000000001153","article-title":"Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma","volume":"84","author":"Norden","year":"2015","journal-title":"Neurology."},{"issue":"5","key":"2024121023462362100_CIT0022","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00280-014-2422-z","article-title":"Recurrent high-grade meningioma: A phase II trial with somatostatin analogue therapy","volume":"73","author":"Sim\u00f3","year":"2014","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"2024121023462362100_CIT0023","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s00259-001-0690-4","article-title":"Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET","volume":"29","author":"Chung","year":"2002","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"2","key":"2024121023462362100_CIT0024","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-011-0759-2","article-title":"Clinical characteristics of meningiomas assessed by 11C-methionine and 18F-fluorodeoxyglucose positron-emission tomography","volume":"107","author":"Arita","year":"2012","journal-title":"J Neurooncol."},{"key":"2024121023462362100_CIT0025","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06783-x","article-title":"Joint EANM\/EANO\/RANO\/SNMMI practice guideline\/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0","author":"Albert","journal-title":"Eur J Nuclear Med Mol Imaging"},{"issue":"12","key":"2024121023462362100_CIT0026","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med."},{"issue":"3","key":"2024121023462362100_CIT0027","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2967\/jnumed.112.111724","article-title":"Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET\/CT within patients with gastroenteropancreatic neuroendocrine tumors","volume":"54","author":"Wild","year":"2013","journal-title":"J Nucl Med."},{"issue":"11","key":"2024121023462362100_CIT0028","doi-asserted-by":"crossref","first-page":"e111624","DOI":"10.1371\/journal.pone.0111624","article-title":"Meningiomas: A comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice","volume":"9","author":"Soto-Montenegro","year":"2014","journal-title":"PLoS One."},{"issue":"11","key":"2024121023462362100_CIT0029","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s00259-023-06315-z","article-title":"Next-generation PET\/CT imaging in meningioma\u2014first clinical experiences using the novel SSTR-targeting peptide [18F]SiTATE","volume":"50","author":"Unterrainer","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"8","key":"2024121023462362100_CIT0030","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med."},{"issue":"3","key":"2024121023462362100_CIT0031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-013-1146-y","article-title":"Correlation between 99mTc-HYNIC-octreotide SPECT\/CT somatostatin receptor scintigraphy and pathological grading of meningioma","volume":"113","author":"Wang","year":"2013","journal-title":"J Neurooncol."},{"issue":"10","key":"2024121023462362100_CIT0032","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","article-title":"Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours","volume":"34","author":"Buchmann","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"2024121023462362100_CIT0033","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.2967\/jnumed.117.191932","article-title":"Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET\/CT compared with contrast-enhanced MRI","volume":"58","author":"Kunz","year":"2017","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023462362100_CIT0034","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/neuros\/nyaa333","article-title":"Simpson grade revisited - intraoperative estimation of the extent of resection in meningiomas versus postoperative somatostatin receptor positron emission tomography\/computed tomography and magnetic resonance imaging","volume":"88","author":"Ueberschaer","year":"2020","journal-title":"Neurosurgery."},{"issue":"1","key":"2024121023462362100_CIT0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00259-023-06400-3","article-title":"Postoperative [68Ga]Ga-DOTA-TATE PET\/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1","volume":"51","author":"Teske","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023462362100_CIT0036","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1152\/ajplegacy.1940.128.3.565","article-title":"Radioactive iodine as an indicator in thyroid physiology: Iodine collection by normal and hyperplastic thyroids in rabbits","volume":"128","author":"Hertz","year":"1940","journal-title":"Am J Physiol-Legacy Content"},{"issue":"11","key":"2024121023462362100_CIT0037","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1007\/s00259-023-06274-5","article-title":"The EANM guideline on radioiodine therapy of benign thyroid disease","volume":"50","author":"Campenn\u00ec","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"2024121023462362100_CIT0038","first-page":"15N","article-title":"SNMMI procedure standard\/EANM practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: Abbreviated version","volume":"63","author":"Avram","year":"2022","journal-title":"J Nucl Med."},{"issue":"12","key":"2024121023462362100_CIT0039","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med."},{"issue":"S2","key":"2024121023462362100_CIT0040","doi-asserted-by":"crossref","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","article-title":"LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)","volume":"34","author":"Sartor","year":"2023","journal-title":"Ann Oncol."},{"issue":"1","key":"2024121023462362100_CIT0041","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/1078-1439(95)00002-Y","article-title":"Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues","volume":"1","author":"Wright","year":"1995","journal-title":"Urol Oncol."},{"issue":"2","key":"2024121023462362100_CIT0042","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","article-title":"Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis","volume":"15","author":"Mannweiler","year":"2009","journal-title":"Pathol Oncol Res."},{"issue":"10231","key":"2024121023462362100_CIT0043","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet."},{"issue":"5","key":"2024121023462362100_CIT0044","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00428-002-0609-x","article-title":"Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis","volume":"440","author":"Papotti","year":"2002","journal-title":"Virchows Arch."},{"issue":"1","key":"2024121023462362100_CIT0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/107327480601300108","article-title":"Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: Immunohistochemical approach with potential clinical utility","volume":"13","author":"Nasir","year":"2006","journal-title":"Cancer Control"},{"issue":"29","key":"2024121023462362100_CIT0046","doi-asserted-by":"crossref","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"2024121023462362100_CIT0047","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177 lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med."},{"issue":"S7","key":"2024121023462362100_CIT0048","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1013","article-title":"887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol."},{"key":"2024121023462362100_CIT0049","doi-asserted-by":"crossref","first-page":"LBA588","DOI":"10.1200\/JCO.2024.42.3_suppl.LBA588","article-title":"[177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study","volume":"42","author":"Singh","year":"2024","journal-title":"J Clin Oncol."},{"issue":"11","key":"2024121023462362100_CIT0050","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood-tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"6","key":"2024121023462362100_CIT0051","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/s41571-023-00756-z","article-title":"Understanding the activity of antibody\u2013drug conjugates in primary and secondary brain tumours","volume":"20","author":"Mair","year":"2023","journal-title":"Nat Rev Clin Oncol."},{"key":"2024121023462362100_CIT0052","doi-asserted-by":"crossref","first-page":"103395","DOI":"10.1016\/j.critrevonc.2021.103395","article-title":"Radioimmunotherapy of glioblastoma multiforme - Current status and future prospects","volume":"163","author":"Li","year":"2021","journal-title":"Crit Rev Oncol Hematol."},{"issue":"6","key":"2024121023462362100_CIT0053","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s13139-019-00618-6","article-title":"Radioimmunotherapy (RIT) in brain tumors","volume":"53","author":"Gholamrezanezhad","year":"2019","journal-title":"Nucl Med Mol Imaging"},{"issue":"8","key":"2024121023462362100_CIT0054","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/pharmaceutics11080376","article-title":"Beyond the barrier: Targeted radionuclide therapy in brain tumors and metastases","volume":"11","author":"Puttemans","year":"2019","journal-title":"Pharmaceutics"},{"issue":"11","key":"2024121023462362100_CIT0055","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.3390\/ijms21113849","article-title":"Theragnostic aspects and radioimmunotherapy in pediatric tumors","volume":"21","author":"Cimini","year":"2020","journal-title":"Int J Mol Sci ."},{"issue":"9","key":"2024121023462362100_CIT0056","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/RLU.0000000000001763","article-title":"Combination of 177Lu-PSMA-617 and external radiotherapy for the treatment of cerebral metastases in patients with castration-resistant metastatic prostate cancer","volume":"42","author":"Wei","year":"2017","journal-title":"Clin Nucl Med."},{"issue":"1","key":"2024121023462362100_CIT0057","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-6-94","article-title":"Successful radiopeptide targeting of metastatic anaplastic meningioma: Case report","volume":"6","author":"Sabet","year":"2011","journal-title":"Radiat Oncol."},{"issue":"3","key":"2024121023462362100_CIT0058","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/RLU.0000000000000669","article-title":"Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT","volume":"40","author":"Makis","year":"2015","journal-title":"Clin Nucl Med."},{"issue":"6","key":"2024121023462362100_CIT0059","doi-asserted-by":"crossref","first-page":"e184","DOI":"10.1097\/RLU.0000000000002077","article-title":"Lung metastases of intracranial atypical meningioma diagnosed on posttherapeutic imaging after 177Lu-DOTATATE Therapy","volume":"43","author":"Backhaus","year":"2018","journal-title":"Clin Nucl Med."},{"issue":"11","key":"2024121023462362100_CIT0060","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00270-019-02262-1","article-title":"Will 177Lu-DOTATATE treatment become more effective in salvage meningioma patients, when boosting somatostatin receptor saturation? a promising case on intra-arterial administration","volume":"42","author":"Braat","year":"2019","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"2","key":"2024121023462362100_CIT0061","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4274\/mirt.galenos.2020.69783","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE in a case of concurrent neuroendocrine tumors and meningioma: Achieving two things in a single action","volume":"30","author":"Assadi","year":"2021","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"11","key":"2024121023462362100_CIT0062","doi-asserted-by":"crossref","first-page":"e692","DOI":"10.1097\/RLU.0000000000004307","article-title":"Management of a patient with metastatic gastrointestinal neuroendocrine tumor and meningioma submitted to peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"47","author":"Pirisino","year":"2022","journal-title":"Clin Nucl Med."},{"issue":"10","key":"2024121023462362100_CIT0063","first-page":"1599","article-title":"Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma","volume":"47","author":"van Essen","year":"2006","journal-title":"J Nucl Med."},{"issue":"9","key":"2024121023462362100_CIT0064","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","article-title":"Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma","volume":"36","author":"Bartolomei","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"12","key":"2024121023462362100_CIT0065","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with 177Lu-DOTATATE: The IEO phase I-II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024121023462362100_CIT0066","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1748-717X-7-99","article-title":"Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"7","author":"Kreissl","year":"2012","journal-title":"Radiat Oncol."},{"key":"2024121023462362100_CIT0067","first-page":"29","article-title":"Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"22","author":"Hartrampf","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"issue":"8","key":"2024121023462362100_CIT0068","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-012-2124-x","article-title":"PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma","volume":"39","author":"H\u00e4nscheid","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"2024121023462362100_CIT0069","first-page":"193","article-title":"Peptide receptor radionuclide therapy in patients with inoperable meningiomas: Our experience and review of the literature","volume":"29","author":"Minutoli","year":"2014","journal-title":"Cancer Biother Radiopharm."},{"issue":"11","key":"2024121023462362100_CIT0070","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","article-title":"90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas","volume":"56","author":"Gerster-Gilli\u00e9ron","year":"2015","journal-title":"J Nucl Med."},{"issue":"2","key":"2024121023462362100_CIT0071","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor\u2013targeted radiopeptide therapy with 90 Y-DOTATOC and 177 Lu-DOTATOC in Progressive Meningioma: Long-term results of a phase ii clinical trial","volume":"56","author":"Marincek","year":"2015","journal-title":"J Nucl Med."},{"issue":"11","key":"2024121023462362100_CIT0072","first-page":"1538","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: Benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"Seystahl","year":"2016","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024121023462362100_CIT0073","doi-asserted-by":"crossref","first-page":"160","DOI":"10.4103\/wjnm.wjnm_39_18","article-title":"Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography\/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors","volume":"18","author":"Parghane","year":"2019","journal-title":"World J Nucl Med"},{"issue":"5","key":"2024121023462362100_CIT0074","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1055\/a-1200-0989","article-title":"Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma","volume":"59","author":"M\u00fcther","year":"2020","journal-title":"Nuklearmedizin."},{"issue":"6","key":"2024121023462362100_CIT0075","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1097\/RLU.0000000000003627","article-title":"Peptide receptor radionuclide therapy in patients with neurofibromatosis type 2: Initial experience","volume":"46","author":"Kertels","year":"2021","journal-title":"Clin Nucl Med."},{"issue":"8","key":"2024121023462362100_CIT0076","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.3390\/curroncol29080438","article-title":"Somatostatin receptor theranostics for refractory meningiomas","volume":"29","author":"Salgues","year":"2022","journal-title":"Curr Oncol"},{"issue":"4","key":"2024121023462362100_CIT0077","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00259-022-06044-9","article-title":"Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma","volume":"50","author":"Minczeles","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"4","key":"2024121023462362100_CIT0078","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-23-2533","article-title":"Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma","volume":"30","author":"Kurz","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2024121023462362100_CIT0079","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: Report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"Huang","year":"2019","journal-title":"Neuro Oncol"},{"key":"2024121023462362100_CIT0080","first-page":"noae037","article-title":"3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas","author":"Tabouret","year":"2024","journal-title":"Neuro-Oncology."},{"issue":"12","key":"2024121023462362100_CIT0081","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: A review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"2024121023462362100_CIT0082","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13014-023-02300-w","article-title":"Target volume delineation for radiotherapy of meningiomas: An ANOCEF consensus guideline","volume":"18","author":"Martz","year":"2023","journal-title":"Radiat Oncol."},{"issue":"3","key":"2024121023462362100_CIT0083","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter Radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med."},{"issue":"2","key":"2024121023462362100_CIT0084","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): A multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"2024121023462362100_CIT0085","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: A pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023462362100_CIT0086","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4274\/mirt.galenos.2023.38258","article-title":"Initial findings on the use of [225Ac]Ac-DOTATATE therapy as a theranostic application in patients with neuroendocrine tumors","volume":"32","author":"Demirci","year":"2023","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"1","key":"2024121023462362100_CIT0087","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy - A review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem"},{"key":"2024121023462362100_CIT0088","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"Krenning","year":"1999","journal-title":"Ann Oncol."},{"issue":"2","key":"2024121023462362100_CIT0089","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med."},{"issue":"10","key":"2024121023462362100_CIT0090","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s00259-008-0779-0","article-title":"Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases","volume":"35","author":"Limouris","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"2024121023462362100_CIT0091","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.122.264586","article-title":"64Cu treatment planning and 67cu therapy with radiolabeled [64Cu\/67Cu]MeCOSar-octreotate in subjects with unresectable multifocal meningioma: Initial results for human imaging, safety, biodistribution, and radiation dosimetry","volume":"64","author":"Bailey","year":"2023","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023462362100_CIT0092","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13550-020-00623-3","article-title":"PRRT of neuroendocrine tumors: Individualized dosimetry or fixed dose scheme","volume":"10","author":"Haug","year":"2020","journal-title":"EJNMMI Res"},{"issue":"1","key":"2024121023462362100_CIT0093","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-020-05038-9","article-title":"EANM position paper on article 56 of the Council Directive 2013\/59\/Euratom (basic safety standards) for nuclear medicine therapy","volume":"48","author":"Konijnenberg","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"2024121023462362100_CIT0094","first-page":"465","article-title":"Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin\u2019s lymphoma: combined data from 4 clinical trials","volume":"44","author":"Wiseman","year":"2003","journal-title":"J Nucl Med."},{"issue":"1","key":"2024121023462362100_CIT0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40658-017-0193-4","article-title":"Variations in the practice of molecular radiotherapy and implementation of dosimetry: Results from a European survey","volume":"4","author":"Sj\u00f6green Gleisner","year":"2017","journal-title":"EJNMMI Phys"},{"issue":"3","key":"2024121023462362100_CIT0096","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: Initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"10","key":"2024121023462362100_CIT0097","doi-asserted-by":"crossref","first-page":"7089\u20137098","DOI":"10.1007\/s00330-023-09697-8","article-title":"Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy","volume":"33","author":"Boursier","year":"2023","journal-title":"Eur Radiol."},{"issue":"1","key":"2024121023462362100_CIT0098","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"1","key":"2024121023462362100_CIT0099","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2024121023462362100_CIT0100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1215\/15228517-2007-053","article-title":"A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost","volume":"10","author":"Reardon","year":"2008","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024121023462362100_CIT0101","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","article-title":"Clinical experience with alpha-particle emitting 211At: Treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6","volume":"49","author":"Zalutsky","year":"2008","journal-title":"J Nucl Med."},{"issue":"S7","key":"2024121023462362100_CIT0102","doi-asserted-by":"crossref","first-page":"S666","DOI":"10.1016\/j.annonc.2022.07.411","article-title":"277O The ReSPECT-GBMTM phase I\/IIa trial of rhenium-186 nanoliposome (186RNL) in recurrent glioma via convection enhanced delivery (CED) and planned phase IIb trial","volume":"33","author":"Brenner","year":"2022","journal-title":"Ann Oncol."},{"issue":"1","key":"2024121023462362100_CIT0103","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/a-0802-5039","article-title":"Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET\/CT in patients with inoperable meningioma","volume":"58","author":"Verburg","year":"2019","journal-title":"Nuklearmedizin."},{"issue":"3","key":"2024121023462362100_CIT0104","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2967\/jnumed.121.262491","article-title":"Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients","volume":"63","author":"Vonken","year":"2022","journal-title":"J Nucl Med."},{"issue":"01","key":"2024121023462362100_CIT0105","doi-asserted-by":"crossref","first-page":"081","DOI":"10.1055\/s-0038-1676300","article-title":"Intra-arterial peptide receptor radionuclide therapy for neuroendocrine tumor liver metastases","volume":"03","author":"Ebbers","year":"2019","journal-title":"Dig Dis Interv"},{"issue":"2","key":"2024121023462362100_CIT0106","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2967\/jnumed.119.241273","article-title":"Intraarterial peptide receptor radionuclide therapy Using 90Y-DOTATOC for hepatic metastases of neuroendocrine tumors","volume":"62","author":"Lawhn-Heath","year":"2021","journal-title":"J Nucl Med."},{"issue":"2","key":"2024121023462362100_CIT0107","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamaoncol.2022.5985","article-title":"Use of single-arm trials for US Food and drug administration drug approval in oncology, 2002-2021","volume":"9","author":"Agrawal","year":"2022","journal-title":"JAMA Oncol"},{"issue":"9","key":"2024121023462362100_CIT0108","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating the theranostic concept to neuro-oncology: disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"2024121023462362100_CIT0109","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: A Quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst."},{"issue":"1","key":"2024121023462362100_CIT0110","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/BF00435979","article-title":"The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires","volume":"5","author":"Osoba","year":"1996","journal-title":"Qual Life Res."},{"issue":"3","key":"2024121023462362100_CIT0111","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/1078-0432.CCR-19-2109","article-title":"Everolimus and octreotide for patients with recurrent meningioma: Results from the phase II CEVOREM trial","volume":"26","author":"Graillon","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2024121023462362100_CIT0112","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","article-title":"Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A Pilot Study","volume":"55","author":"Wild","year":"2014","journal-title":"J Nucl Med."},{"issue":"4","key":"2024121023462362100_CIT0113","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2967\/jnumed.123.266817","article-title":"Radiolabeled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with therapy-resistant meningioma: PROMENADE Phase 0 Study","volume":"65","author":"Eigler","year":"2024","journal-title":"J Nucl Med."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae069\/57400812\/noae069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/Supplement_9\/S215\/61000388\/noae069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/Supplement_9\/S215\/61000388\/noae069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T18:47:07Z","timestamp":1733856427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/Supplement_9\/S215\/7664448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,4]]},"references-count":113,"journal-issue":{"issue":"Supplement_9","published-online":{"date-parts":[[2024,5,4]]},"published-print":{"date-parts":[[2024,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae069","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,5,4]]}}}